Endocrinology and metabolism (Seoul, Korea)最新文献

{"title":"Association of Multiple Obesity-Related Composite Indices with All-Cause Mortality in Patients with Stage 0-3 Cardiovascular-Kidney-Metabolic Syndrome.","authors":"Jianmin Lu, Jiajin Yang, Zhuoyi Peng, Cilu Huang, Yue Chen, Chuanzhao Zhang, Baohua Hou, Xiaoqing He, Shanzhou Huang","doi":"10.3803/EnM.2025.2711","DOIUrl":"https://doi.org/10.3803/EnM.2025.2711","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to determine the predictive ability of eight composite obesity-related indices for all-cause mortality in adults with cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3, given the inadequacy of conventional anthropometric measures.</p><p><strong>Methods: </strong>We conducted a prospective cohort study using UK Biobank data, including 261,742 adults with CKM stages 0-3 at baseline. Eight indices (body mass index, relative fat mass [RFM], body roundness index [BRI], lipid accumulation product [LAP], visceral adiposity index, cardiometabolic index [CMI], atherogenic index of plasma, and triglyceride-glucose index) were evaluated using multivariable logistic regression, Cox proportional hazards models, receiver operating characteristic analysis, and restricted cubic spline (RCS) modeling to examine their associations with, and predictive ability for, all-cause mortality.</p><p><strong>Results: </strong>During follow-up, 13,437 deaths (5.1%) occurred. All eight indices were positively associated with mortality (P<0.001). BRI was the strongest predictor (area under the curve [AUC]=0.658; optimal cutoff=4.515), outperforming LAP (AUC=0.616) and CMI (AUC=0.610). RFM exhibited the lowest discriminative ability (AUC=0.502). Higher quartiles of most indices were associated with progressively increased mortality risk, with BRI demonstrating consistent predictive value across subgroups in RCS analyses.</p><p><strong>Conclusion: </strong>BRI showed the strongest and most consistent association with all-cause mortality in CKM stages 0-3, suggesting that it may act as a robust tool for early risk stratification and support targeted prevention strategies.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Follow-up Course of 17α-Hydroxylase/17,20-Lyase Deficiency in Korea: the OUTSPREAD Multicenter Study.","authors":"Ka Young Kim, Sung Yoon Cho, Min Jee Kim, Hwa Young Kim, Junghwan Suh, Chong Kun Cheon, Hyo-Kyoung Nam, Choong Ho Shin, Young Ah Lee, Yun Jeong Lee","doi":"10.3803/EnM.2025.2703","DOIUrl":"https://doi.org/10.3803/EnM.2025.2703","url":null,"abstract":"<p><strong>Background: </strong>17α-Hydroxylase/17,20-lyase deficiency (17OHD) is a rare congenital adrenal hyperplasia with cortisol and sex steroid deficiency and mineralocorticoid excess. We aimed to describe the phenotypic spectrum and clinical course of Korean patients with 17OHD in a multicenter cohort.</p><p><strong>Methods: </strong>This retrospective study included 17 patients with genetically confirmed 17OHD from six tertiary centers in Korea. Demographic, biochemical, and genetic data were reviewed to evaluate clinical variability and long-term outcomes.</p><p><strong>Results: </strong>Of the 17 patients, seven had a 46,XX karyotype and 10 had a 46,XY karyotype; all had female external genitalia and were raised as females. Primary amenorrhea predominated in 46,XX patients; 46,XY patients presented variably (hypertension and hyperpigmentation). The median age at diagnosis was 16.4 years. Higher follicle-stimulating hormone levels (54.2 mIU/mL vs. 18.2 mIU/mL, P=0.003) and less frequent hypokalemia (40.0% vs. 85.7%, P=0.038) were observed in 46,XY patients compared with 46,XX. The most frequent genotype was c.1118A>T (55.9%). At diagnosis, 58.8% of the patients exhibited hypokalemia, resolved with treatment. During a median follow-up of 8.1 years, 82.4% had hypertension, and 57.1% achieved normal blood pressure with glucocorticoids and/or antihypertensives. Low bone mineral density was found in 46.2% of the patients, and improvement with sex hormone replacement was observed. Gonadectomy was performed in nine XY patients (90.0%), with no malignancies identified.</p><p><strong>Conclusion: </strong>Patients with 17OHD commonly present with hypergonadotropic hypogonadism, hypertension, and hypokalemia; however, phenotypic variability exists. Clinicians should consider 17OHD in adolescents with delayed puberty and hypertension, even without classical biochemical findings, to ensure timely diagnosis and management.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YTHDF1-Mediated m6A Modification of lncRNA OIP5-AS1 Exacerbates Macrophage Metabolic Dysfunction in Diabetes Mellitus with Coronary Artery Disease.","authors":"Hongjie Wang, Luyao Li, Zhen Zhen, Zheqi Zhang, Ya Su, Bo Li","doi":"10.3803/EnM.2025.2566","DOIUrl":"https://doi.org/10.3803/EnM.2025.2566","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus (DM) with coronary artery disease (CAD), referred to as DM-CAD, is a prevalent endocrine-metabolic condition characterized by macrophage-driven inflammation and metabolic dysregulation. This study aims to investigate the role of YTH N6-methyladenosine RNA binding protein F1 (YTHDF1)-mediated N6-methyladenosine (m6A) modification in stabilizing the long non-coding RNA (lncRNA) Opa interacting protein 5 antisense RNA 1 (OIP5-AS1) and to determine its impact on macrophage metabolic dysfunction in DM-CAD.</p><p><strong>Methods: </strong>Single-cell RNA sequencing and bulk RNA sequencing were performed using DM-CAD mouse models, with downstream analyses conducted using Seurat, CellChat, least absolute shrinkage and selection operator (LASSO) regression, and random forest algorithms. Experimental validation included RNA immunoprecipitation followed by quantitative polymerase chain reaction, actinomycin D-based RNA stability assays, and 2-deoxyglucose (2-DG) interventions in THP-1-derived macrophages, alongside metabolomic profiling and reactive oxygen species (ROS) measurements.</p><p><strong>Results: </strong>Increased macrophage-endothelial cell coupling was observed in DM-CAD, with both OIP5-AS1 and YTHDF1 significantly upregulated and closely associated with glycolytic metabolic pathways. YTHDF1-mediated m6A modification stabilized OIP5-AS1, thereby promoting glycolysis, foam cell formation, ROS production, plaque development, and the upregulation of proinflammatory cytokines, collectively exacerbating atherosclerosis. Notably, treatment with 2-DG markedly reversed these pathological phenotypes.</p><p><strong>Conclusion: </strong>This study identifies the YTHDF1-m6A-OIP5-AS1 axis as a critical regulator of macrophage metabolic dysfunction in DM-CAD, thereby providing an epigenetic framework for understanding disease progression. Targeting this regulatory pathway may attenuate metabolic inflammation and represents a promising therapeutic strategy for endocrine-related cardiovascular complications.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of the Inflammatory Burden Index in the Diagnosis and Prognosis of Subacute Thyroiditis.","authors":"Sumei Wang, Jing Lu, Rui Guo, Xueyang Wang, Bijun Tong, Yan Shen, Hongxiang Xie","doi":"10.3803/EnM.2025.2642","DOIUrl":"https://doi.org/10.3803/EnM.2025.2642","url":null,"abstract":"<p><strong>Background: </strong>This study sought to assess the utility of the inflammatory burden index (IBI) in differentiating subacute thyroiditis (SAT) from Graves' disease (GD) and to investigate its association with recovery time, hepatic function impairment, recurrence, and permanent hypothyroidism in patients with SAT.</p><p><strong>Methods: </strong>Clinical and laboratory data from 357 adult patients with SAT, 412 patients with GD, and 633 healthy controls were retrospectively analyzed. Determinants influencing recovery time, hepatic function impairment, recurrence, and permanent hypothyroidism in patients with SAT were systematically evaluated.</p><p><strong>Results: </strong>The IBI in the SAT cohort was markedly higher than that observed in both patients with GD and healthy controls. Receiver operating characteristic curve analysis indicated that the optimal IBI cutoff value for distinguishing SAT from GD was 9.13, yielding a diagnostic sensitivity of 90.76%, a specificity of 88.35%, and an area under the curve (AUC) of 0.944 (95% confidence interval, 0.927 to 0.961). The AUC for IBI was markedly superior to those for erythrocyte sedimentation rate (ESR), C-reactive protein, systemic immune-inflammation index, and other complete blood count-derived indices. Among patients with painless SAT, the IBI was markedly elevated compared with that in thyroid-stimulating hormone receptor antibody (TRAb)-negative GD patients. Stepwise multiple logistic regression identified ESR, IBI, free thyroxine, and thyroid-stimulating hormone as independent predictive factors for SAT. IBI was not associated with recovery time in patients with SAT. However, higher IBI values were observed in patients requiring glucocorticoid therapy due to an insufficient response to non-steroidal anti-inflammatory drugs. Furthermore, no significant associations were identified between IBI and hepatic function impairment, recurrence, or permanent hypothyroidism in patients with SAT.</p><p><strong>Conclusion: </strong>IBI, as a simple and practical inflammatory biomarker, could potentially serve as a valuable diagnostic tool for differentiating SAT, particularly in diagnostically challenging cases. Moreover, it may have clinical relevance in guiding therapeutic decision- making for patients with SAT.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Prolactinoma and Incident Type 2 Diabetes Mellitus: Evidence from a Korean Nationwide Cohort.","authors":"Han Na Jung, Bo Ram Yang, Min-Seon Kim, Jeong-Hwa Yoon, Se Hee Min","doi":"10.3803/EnM.2025.2508","DOIUrl":"https://doi.org/10.3803/EnM.2025.2508","url":null,"abstract":"<p><strong>Background: </strong>The effect of prolactinoma on the development of type 2 diabetes mellitus (T2DM) has not been evaluated at the population level. We investigated the association between prolactinoma and incident T2DM in a nationwide cohort.</p><p><strong>Methods: </strong>We analyzed data from the Korean National Health Insurance Service-National Sample Cohort, which includes 2% of the total national population selected by random sampling, covering the period from 2002 to 2019. A total of 335 patients with newly diagnosed prolactinoma and 1,562 age- and sex-matched controls were included. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for T2DM using Cox proportional hazards regression. Time-dependent HRs were also estimated.</p><p><strong>Results: </strong>The proportion of prolactinoma patients who developed T2DM was significantly higher than that of controls (10.1% vs. 5.5%; relative risk, 1.84; 95% CI, 1.26 to 2.69). After adjustment for age, sex, income, and comorbidities, the risk of T2DM remained significantly higher in the prolactinoma group (HR, 1.56; 95% CI, 1.01 to 2.41). Subgroup analysis showed a markedly increased risk among individuals aged ≥50 years (HR, 4.47; 95% CI, 1.66 to 12.08). The positive association between prolactinoma and T2DM decreased over time but remained significant for up to 3 years after prolactinoma diagnosis (HR, 9.28 [95% CI, 3.45 to 24.97]; HR, 3.15 [95% CI, 1.55 to 6.38]; and HR, 0.82 [95% CI, 0.44 to 1.53] for ≤1, 1-3, and >3 years, respectively).</p><p><strong>Conclusion: </strong>Newly diagnosed prolactinoma was independently associated with a higher risk of T2DM, with the association diminishing over 3 years. These findings highlight the importance of monitoring for T2DM during the early management of prolactinoma, particularly in middle-aged patients who may have been previously overlooked.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anabolics in Cancer Patients: To Use or Not to Use?","authors":"A Ram Hong","doi":"10.3803/EnM.2026.3027","DOIUrl":"https://doi.org/10.3803/EnM.2026.3027","url":null,"abstract":"<p><p>With improving cancer survival, the management of osteoporosis in cancer survivors has become increasingly important. Cancer treatment-induced bone loss and aging place many survivors at high risk of fragility fractures. Anabolic agents, including parathyroid hormone (PTH) receptor agonists and the anti-sclerostin antibody romosozumab, effectively stimulate bone formation and reduce fracture risk in the general population. However, their use in cancer patients remains limited because of safety concerns and insufficient clinical evidence. Preclinical studies suggested a potential risk of osteosarcoma with PTH analogues and possible effects on tumor growth or bone metastasis through modulation of the bone microenvironment, although long-term human studies have not demonstrated an increased malignancy risk. In clinical practice, PTH analogues are generally avoided in patients with active malignancy, bone metastases, hypercalcemia, or a history of osteosarcoma. In selected cancer survivors with a sufficiently long diseasefree interval, their cautious use may be considered depending on recurrence risk. Romosozumab may represent another potential option, although supporting evidence remains limited. Overall, the use of anabolic therapy in cancer patients should be individualized, carefully balancing fracture risk against potential oncologic safety concerns.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147694606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexpected Cancelation of Radioactive Iodine Treatment after Thyroid Hormone Withdrawal: Lessons from a Case Series.","authors":"Hye-Seon Oh, Won Gu Kim, Won Bae Kim, Jin-Sook Ryu, Min Ji Jeon, Tae Yong Kim","doi":"10.3803/EnM.2025.2798","DOIUrl":"https://doi.org/10.3803/EnM.2025.2798","url":null,"abstract":"<p><strong>Background: </strong>Radioactive iodine treatment (RAIT) is an essential therapy for differentiated thyroid cancer. However, unforeseen complications arising during thyroid hormone withdrawal (THW) can lead to cancelation of the scheduled treatment. This study aimed to identify cases in which THW-RAIT was discontinued due to THW-related complications and to explore potentially preventable causes to improve patient management.</p><p><strong>Methods: </strong>Among 4,174 patients who underwent THW-RAIT between 2012 and 2024, 39 did not complete the planned treatment. After excluding cancelations unrelated to THW, 11 (0.26%) patients with unexpected THW-related medical issues were analyzed.</p><p><strong>Results: </strong>The median age of the included patients was 61 years (range, 23 to 70), and 10 were male. The reasons for THW-RAIT cancelation were hyponatremia (n=1), abnormal liver function (n=1), renal dysfunction (n=3), and combined liver and renal dysfunction (n=6). The patient with hyponatremia was taking a thiazide diuretic. Most cases of liver dysfunction were associated with prior use of herbal medications, whereas renal dysfunction was linked to diuretic or nonsteroidal anti-inflammatory drug use, pre-existing conditions such as single kidney or diabetic nephropathy, or inadequate oral intake during low-iodine preparation. Two cases of concurrent liver and renal dysfunction were attributed to rhabdomyolysis following intense exercise or heavy physical labor.</p><p><strong>Conclusion: </strong>Enhanced patient education, comprehensive pre-treatment assessment, and careful avoidance of high-risk medications are essential to prevent THW-related complications and minimize disruptions in RAIT.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147640624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Weight Loss: Skeletal Considerations in Obesity Treatment.","authors":"Myung Jin Kim, Yun Kyung Cho","doi":"10.3803/EnM.2026.2986","DOIUrl":"https://doi.org/10.3803/EnM.2026.2986","url":null,"abstract":"<p><p>The rapid evolution of obesity therapeutics, led by glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metabolic surgery, has achieved unprecedented weight loss. However, the skeletal consequences of such substantial weight reduction are of increasing clinical concern. This review explores the relationship between obesity, weight-loss modalities, and bone health. While obesity was historically viewed as bone-protective due to mechanical loading, recent evidence highlights qualitative bone deterioration and sitespecific fracture risks. Intentional weight loss through caloric restriction or bariatric surgery consistently accelerates bone turnover and reduces bone mineral density (BMD), with surgical interventions showing the most significant impact. Emerging data on GLP-1RAs suggest modest BMD declines, largely proportional to weight loss and likely driven by mechanical unloading. Conversely, preclinical studies indicate that GLP-1 signaling may exert direct osteoanabolic and anti-resorptive effects. To preserve skeletal integrity, obesity management must shift toward a holistic body composition framework. Integrating structured resistance exercise, optimizing nutrition (calcium, vitamin D, and protein), and implementing skeletal monitoring in high-risk individuals are essential. Future obesity care should prioritize the maintenance of bone quality and lean mass alongside fat reduction to ensure long-term skeletal resilience and prevent fragility fractures.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147641275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Abdominal Myosteatosis and Visceral Fat Obesity with Arterial Stiffness.","authors":"Min Jung Lee, Hong-Kyu Kim, Eun Hee Kim, Sung Jin Bae, Hyo-Jung Nam, Sang Hoon Lee, Chang Hee Jung, Woo Je Lee","doi":"10.3803/EnM.2025.2734","DOIUrl":"https://doi.org/10.3803/EnM.2025.2734","url":null,"abstract":"<p><strong>Background: </strong>Arterial stiffness with aging predicts cardiovascular diseases (CVDs) and target organ damage. While sarcopenia has been linked to arterial stiffness, the association of myosteatosis and visceral adiposity with arterial stiffness remains underexplored. As age-related fat redistribution, including myosteatosis and visceral obesity, often precedes the overt sarcopenia, their early evaluation may be beneficial in preventing arterial stiffness. Therefore, this cross-sectional study aimed to assess whether myosteatosis and visceral obesity are associated with increased arterial stiffness.</p><p><strong>Methods: </strong>A total of 6,004 subjects without CVD who underwent abdominal computed tomography and brachial-ankle pulse wave velocity (baPWV) between 2012 and 2013 during health examinations were included. Visceral fat area and total abdominal muscle area (TAMA) were measured at the L3 vertebral level. Muscle quality was assessed using the normal attenuation muscle area (NAMA)/TAMA index, where a lower value indicates a reduced proportion of healthy muscle (NAMA) and a higher presence of myosteatosis.</p><p><strong>Results: </strong>After adjusting for multiple cardiovascular risk factors, including myosteatosis, visceral obesity was significantly associated with elevated baPWV in men (odds ratio [OR]=1.32; 95% confidence interval [CI]=1.10 to 1.60; P=0.004). In contrast, in women, myosteatosis was significantly associated with elevated baPWV in a fully adjusted model that included visceral obesity (OR=3.26; 95% CI=1.13 to 9.44; P=0.029).</p><p><strong>Conclusion: </strong>Ectopic fat infiltration, including visceral obesity and myosteatosis, was significantly associated with increased arterial stiffness. Notably, visceral obesity was significantly associated with elevated baPWV in men, while myosteatosis was significant in women after adjustment.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147641279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Muscle Loss Driven by Extracellular Signal-Regulated Kinase Suppression via β-Adrenergic Activation in High-Normal Catecholamine Status.","authors":"Jieun Lee, Ju Yeon Kwak, Ho Yeop Lee, Ji Sun Moon, Hyo Ju Jang, Ha Thi Nga, Thi Linh Nguyen, Alfin Mohammad Abdillah, Junglyun Kim, Sihwan Kim, Yong Ryoul Yang, Jeong Eun Lee, Hyon-Seung Yi","doi":"10.3803/EnM.2025.2527","DOIUrl":"https://doi.org/10.3803/EnM.2025.2527","url":null,"abstract":"<p><strong>Background: </strong>Catecholamines play a crucial role in muscle biogenesis, but their persistent elevation is linked to muscle wasting, which is poorly understood. This study aimed to investigate the association between catecholamine levels and age-related muscle loss.</p><p><strong>Methods: </strong>This retrospective study evaluated the plasma levels of two catecholamines, metanephrine and normetanephrine, and the clinical characteristics of 830 patients with adrenal incidentaloma on computed tomography (CT). Cross-sectional CT data at the L3 lumbar vertebrae were used to measure muscle areas. In vitro studies on C2C12 myotubes were conducted to examine β-adrenergic receptor signaling pathways and their role in myogenesis.</p><p><strong>Results: </strong>Men had significantly higher mean metanephrine levels of 0.17 nmol/L and normetanephrine levels of 0.63 nmol/L than women (P<0.05). Total abdominal muscle area was negatively correlated with catecholamine levels in both men and women, with the strongest negative correlation between normetanephrine levels and total abdominal muscle area in men (r=-0.31, P<0.001). Similarly, the strongest negative correlation between visceral fat area and metanephrine was observed in men (r=-0.25, P=0.004). Clenbuterol, a β-adrenergic receptor agonist, inhibited myogenesis, including myotube formation by extracellular signal-regulated kinase (ERK) suppression in C2C12 myoblasts. Conversely, β-blockers increased myogenesis via increasing ERK phosphorylation in C2C12 cells. These findings suggest that β-adrenergic modulation influences skeletal muscle differentiation, with ERK phosphorylation.</p><p><strong>Conclusion: </strong>Catecholamine levels are associated with age, sex, muscle mass, and fat mass. Monitoring catecholamine levels, particularly in older men and in individuals with reduced muscle mass, may help manage age-related muscle loss and lead to individualized treatment strategies.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147625253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}